Mode
Text Size
Log in / Sign up

Secondary Analysis Shows Remote Ischaemic Conditioning Benefit in Non-Smokers With Acute Ischaemic Stroke

Secondary Analysis Shows Remote Ischaemic Conditioning Benefit in Non-Smokers With Acute Ischaemic S…
Photo by Alexander Grey / Unsplash
Key Takeaway
Consider remote ischaemic conditioning cautiously in non-smokers with acute stroke, noting this is a post hoc subgroup analysis.

This study represents a secondary analysis of a randomized controlled trial involving 1717 patients with acute moderate ischaemic stroke. Participants had National Institutes of Health Stroke Scale scores between 6 and 16 and did not undergo reperfusion therapy. The cohort included 505 current smokers and 1212 non-smokers.

Patients received remote ischaemic conditioning administered twice daily for 14 days compared with standard treatment. The primary outcome was excellent functional prognosis at 90 days defined by modified Rankin Scale scores 0-1. In non-smokers, remote ischaemic conditioning significantly increased the proportion achieving this outcome compared with control, with an adjusted odds ratio of 1.487. Absolute numbers were 69.1% versus 62.8%, with a 95% confidence interval of 1.143 to 1.936 and p=0.003.

Among current smokers, there was no significant difference compared with control. The adjusted odds ratio was 1.154 with absolute numbers of 64.1% versus 62.1%. The 95% confidence interval ranged from 0.791 to 1.684 with p=0.46. The interaction between smoking status and remote ischaemic conditioning efficacy showed no significant association with a P for interaction of 0.50.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported. Key limitations include that this is a post hoc subgroup analysis of a randomized controlled trial rather than a primary trial.

Study Details

Study typeRct
Sample sizen = 505
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Remote ischaemic conditioning (RIC) is a potential non-invasive neuroprotective strategy, but it remains unclear whether its efficacy is influenced by smoking status. This study explored the impact of smoking status on the therapeutic effect of RIC in patients with acute moderate ischaemic stroke through a post hoc subgroup analysis. METHODS: Based on the data from the Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke trial, 1717 patients with moderate stroke (National Institutes of Health Stroke Scale score 6-16) who did not undergo reperfusion therapy were included and categorised into current smokers (n=505) and non-smokers (n=1212) based on their smoking status. Patients were randomly assigned to receive either RIC (administered twice daily for 14 days) or standard treatment. The primary outcome was excellent functional prognosis at 90 days (modified Rankin Scale, mRS scores 0-1). Multivariable regression analysis was used to evaluate the interaction between smoking status and RIC. RESULTS: Among non-smokers, RIC significantly increased the proportion of patients achieving mRS 0-1 at 90 days (69.1% vs 62.8%; adjusted OR 1.487, 95% CI 1.143 to 1.936; p=0.003). Among current smokers, there was no significant difference in the proportion of mRS 0-1 at 90 days compared with the control group (64.1% vs 62.1%; adjusted OR 1.154, 95% CI 0.791 to 1.684; p=0.46). The interaction analysis revealed no significant association between smoking status and RIC efficacy (P for interaction=0.50). CONCLUSIONS: In this analysis, RIC significantly improved the excellent functional prognosis of non-smoking stroke patients, but had no significant benefit for current smokers, suggesting that smoking may attenuate RIC efficacy. TRIAL REGISTERATION NUMBER: NCT03740971.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.